{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T02:39:29Z","timestamp":1782959969562,"version":"3.54.5"},"reference-count":139,"publisher":"Informa UK Limited","issue":"9","funder":[{"name":"funding"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2021,9,2]]},"DOI":"10.1080\/14737140.2021.1953986","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T08:26:57Z","timestamp":1625732817000},"page":"941-956","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Pembrolizumab in the treatment of refractory primary mediastinal large B-cell lymphoma: safety and efficacy"],"prefix":"10.1080","volume":"21","author":[{"given":"Vincent","family":"Camus","sequence":"first","affiliation":[{"name":"D\u00e9partement D\u2019h\u00e9matologie, Centre Henri Becquerel, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Bigenwald","sequence":"additional","affiliation":[{"name":"D\u00e9partement D\u2019h\u00e9matologie, Institut Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Ribrag","sequence":"additional","affiliation":[{"name":"D\u00e9partement D\u2019h\u00e9matologie, Institut Gustave Roussy, Villejuif, France"},{"name":"D\u00e9partement d\u2019Innovation Th\u00e9rapeutique Et Des Essais Pr\u00e9coces (DITEP), Institut Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Lazarovici","sequence":"additional","affiliation":[{"name":"D\u00e9partement D\u2019h\u00e9matologie, Institut Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Jardin","sequence":"additional","affiliation":[{"name":"D\u00e9partement D\u2019h\u00e9matologie, Centre Henri Becquerel, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mentine","family":"Sarkozy","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019Innovation Th\u00e9rapeutique Et Des Essais Pr\u00e9coces (DITEP), Institut Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,8,18]]},"reference":[{"key":"cit0001","first-page":"2375","volume":"127","author":"Swerdlow SH","year":"2016","journal-title":"Blood Am Soc Hematol"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001126"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002067"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-428896"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-11-812073"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-610436"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282780"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.985673"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.4482"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-535443"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.111203"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.298"},{"key":"cit0013","volume-title":"R-CHOP14 As a Standard of Care in Primary Mediastinal B Cell Lymphoma: a 10-YEARS Experience of Lysa Centers","author":"Camus V","year":"2020"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.06.009"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3467"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000324"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(80)90294-6"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-198603000-00005"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1007\/BF00705408"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.1986.tb02491.x"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-293050"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199607000-00012"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2010.08.017"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.10.3567.422k06_3567_3575"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1097\/01.MP.0000032534.81894.B3"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2017.07.010"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.09.044"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.05.013"},{"issue":"9","key":"cit0031","first-page":"1091","volume":"89","author":"Malpeli G","journal-title":"Haematologica"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031074"},{"issue":"4","key":"cit0033","volume":"30","author":"TF B MB","year":"2001","journal-title":"Genes Chromosomes Cancer"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13033"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-1841"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1038\/nature09754"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4742"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.0917"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.10.008"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0201"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2900"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-808907"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001923"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1006-1"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13789.Epub2021Jun17"},{"issue":"5","key":"cit0046","first-page":"v116","volume":"26","author":"Tilly H","journal-title":"Ann Oncol"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw175"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.802784"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3758-5"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2016.09.031"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-575092"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.192492"},{"key":"cit0053","unstructured":"Vassilakopoulos TP, Papageorgiou SG, Angelopoulou MK, et al. Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies. Ann Hematol [Internet]. 2021 Feb 1 [cited 2021 Jun 11]. Available from: http:\/\/link.springer.com\/10.1007\/s00277-021-04421\u20132"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.120"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2016.1139703"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.145102"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802203788"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214561"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.2689.2689"},{"key":"cit0060","unstructured":"Hayden A, Tonseth P, Lee DG, et al. Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET adapted approach. Blood [Internet]. 2020 Jun 30 [cited 2020 Nov 2]. Available from: https:\/\/ashpublications.org\/blood\/article\/doi\/10.1182\/blood.2019004296\/461229\/Outcome-of-Primary-Mediastinal-Large-Bcell"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61040-4"},{"key":"cit0062","volume-title":"DA-EPOCH-R VS R-CHOP in Patients with Primary Mediastinal Large B-Cell Lymphoma: results of Prospective Randomized Ukrainian Multicenter Study","author":"Stepanishyna Y","year":"2020"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.746684"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-791566"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2012.10.037"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15731"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.02.006"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004296"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.550073"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2347"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-3024-8"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1519812"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13337"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8041"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703401"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05661.x"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1080\/10245332.2016.1258846"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-017-0063-7"},{"key":"cit0079","unstructured":"Le Gouill S, Ghesquieres H, Ob\u00e9ric L, et al. Obinutuzumab versus rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA. Blood [Internet]. 2020 Nov 19 [cited 2020 Dec 7]. Available from: https:\/\/ashpublications.org\/blood\/article\/doi\/10.1182\/blood.2020008750\/474212\/Obinutuzumab-versus-Rituximab-in-young-patients"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1002\/hon.77_2630"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-278796"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.04.093"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.2.312"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.9174"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22634"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007766"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.101"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802108870"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V108.11.3057.3057"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1646"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.06.009"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.2.717"},{"key":"cit0093","volume-title":"High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) with Consolidative Radiation Therapy (RT) for Relapsed or Refractory (R\/R) Primary Mediastinal B-Cell Lymphoma (PMBCL): 20-Year Experience at MD Anderson Cancer Center (MDACC)","author":"Saini N","year":"2020"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0111-6"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-719641"},{"key":"cit0096","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-142349","volume-title":"Ctdna Monitoring in Predicting Relapse of Primary Mediastinal B-Cell Lymphoma","author":"Pang D","year":"2020"},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000239"},{"issue":"1","key":"cit0098","first-page":"1","volume":"7","author":"Lee JY","journal-title":"Nat Commun"},{"issue":"1","key":"cit0099","first-page":"1","volume":"8","author":"Tan S","journal-title":"Nat Commun"},{"issue":"6","key":"cit0100","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1158\/1535-7163.MCT-19-0774","volume":"19","author":"Hutchins B","journal-title":"Mol Cancer Ther"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz011"},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00934"},{"key":"cit0103","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-758383"},{"issue":"1","key":"cit0104","first-page":"1","volume":"5","author":"Freshwater T","journal-title":"J Immunother Cancer"},{"key":"cit0105","volume-title":"Pembrolizumab Monotherapy in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): 3-Year Follow-up of the Keynote-170 Study","author":"Zinzani PL","year":"2020"},{"key":"cit0106","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"cit0107","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"cit0108","unstructured":"FDA approves pembrolizumab for treatment of relapsed or refractory PMBCL | FDA [internet]. [cited 2020 Dec 3]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-treatment-relapsed-or-refractory-pmbcl"},{"key":"cit0109","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2836"},{"key":"cit0110","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"cit0111","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.3994"},{"key":"cit0112","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30167-X"},{"key":"cit0113","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.2.711"},{"key":"cit0114","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.2.945"},{"key":"cit0115","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24951"},{"key":"cit0116","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008211"},{"key":"cit0117","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008553"},{"key":"cit0118","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596"},{"key":"cit0119","volume-title":"CCR Drug Updates FDA Approval Summary: pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors","author":"Marcus L","year":"2019"},{"key":"cit0120","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1803"},{"key":"cit0121","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708984"},{"key":"cit0122","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-811224"},{"key":"cit0123","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01492"},{"key":"cit0124","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802108870"},{"key":"cit0125","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-764258"},{"key":"cit0126","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/1538-7445.AM2017-5588","author":"Cao AT","year":"2017","journal-title":"Cancer Res"},{"key":"cit0127","first-page":"1789","author":"Heiser RA","year":"2018","journal-title":"American Association for Cancer Research (AACR)"},{"key":"cit0128","unstructured":"FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma | FDA [internet]. [cited 2020 Dec 22]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-car-t-cell-therapy-treat-adults-certain-types-large-b-cell-lymphoma"},{"key":"cit0129","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-140054","volume-title":"Checkpoint Inhibition before Axicabtagene Ciloleucel Cell Therapy in Primary Mediastinal B-Cell Lymphoma (PMBCL) Treated in Real Life Setting","author":"Chiappella A","year":"2020"},{"key":"cit0130","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136751"},{"key":"cit0131","volume-title":"Phase 1 Alexander Study of AUTO3, the First CD19\/22 Dual Targeting CAR T Cell Therapy, with Pembrolizumab in Patients with Relapsed\/ Refractory (r\/r) DLBCL","author":"Ramakrishnan A","year":"2020"},{"key":"cit0132","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129120"},{"key":"cit0133","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-119502"},{"key":"cit0134","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.7519"},{"key":"cit0135","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16494"},{"key":"cit0136","doi-asserted-by":"publisher","DOI":"10.1177\/0300060520945075"},{"key":"cit0137","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15051"},{"key":"cit0138","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.7519"},{"key":"cit0139","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000215"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2021.1953986","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T09:21:08Z","timestamp":1672737668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2021.1953986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,18]]},"references-count":139,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9,2]]}},"alternative-id":["10.1080\/14737140.2021.1953986"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2021.1953986","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-04-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}